Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
246.27
-2.89 (-1.16%)
Jan 17, 2025, 4:00 PM EST - Market closed
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 23 analysts with 12-month price forecasts for ALNY stock have an average target of 299.09, with a low estimate of 170 and a high estimate of 400. The average target predicts an increase of 21.45% from the current stock price of 246.27.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ALNY stock from 24 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 10 | 10 | 10 | 10 | 10 |
| Buy | 6 | 6 | 7 | 7 | 7 | 8 |
| Hold | 7 | 7 | 6 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 23 | 23 | 23 | 23 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $400 | Strong Buy | Reiterates | $400 | +62.42% | Jan 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $320 | Strong Buy | Reiterates | $320 | +29.94% | Jan 13, 2025 |
| Bernstein | Bernstein | Buy Maintains $314 → $310 | Buy | Maintains | $314 → $310 | +25.88% | Jan 7, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $296 | Buy | Reiterates | $296 | +20.19% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $400 | Strong Buy | Reiterates | $400 | +62.42% | Nov 18, 2024 |
Financial Forecast
Revenue This Year
2.28B
from 1.83B
Increased by 24.87%
Revenue Next Year
2.71B
from 2.28B
Increased by 18.53%
EPS This Year
-2.05
from -3.52
EPS Next Year
-1.25
from -2.05
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.5B | 3.6B | 4.8B | |||
| Avg | 2.3B | 2.7B | 3.6B | |||
| Low | 2.0B | 2.2B | 2.8B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 34.3% | 59.7% | 77.0% | |||
| Avg | 24.9% | 18.5% | 32.6% | |||
| Low | 11.2% | -3.2% | 4.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.84 | 2.83 | 6.47 | |||
| Avg | -2.05 | -1.25 | 2.58 | |||
| Low | -2.88 | -3.63 | -0.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.